Phase I/II dose-escalation trial of patupilone every 3 weeks in patients with relapsed/refractory ovarian cancer.

被引：0

作者：

Smit, WM

Sufliarsky, J

Spanik, S

Wagnerová, M

Kaye, S

Oza, AM

Gore, M

Williams, K

Johri, A

Huinink, WWT

机构：

[1] Med Spectrum Twente, Enschede, Netherlands

[2] Natl Canc Inst, Bratislava, Slovakia

[3] St Elisabeth Canc Inst, Bratislava, Slovakia

[4] Inst Oncol, Kosice, Slovakia

[5] Royal Marsden Hosp, Sutton, Surrey, England

[6] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada

[7] Novartis Pharmaceut AG, Basel, Switzerland

[8] Novartis Pharmaceut Corp, E Hanover, NJ USA

[9] Netherlands Canc Inst, Amsterdam, Netherlands

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：468S / 468S

页数：1